MT-141に関する臨床的研究

概要

論文の詳細を見る
MT-141, a new antibiotic of the cephamycin group, was employed in the treatment of internal infectious disease, and clinical efficacy of the drug was investigated.<BR>Twenty five patients with infections (Pneumonia 7 cases, RTI 3 cases, UTI 15 cases) were treated with MT-141 at a daily dose of 2 g twice a day by intravenous drip infusion. These patients consisted of 12 males and 13 females, and they ranged in age from 65 to 97 years (mean age: 78.6 years). The MT-141 therapy was continued for 6 to 23 days (mean duration: 10.9 days) and the total dosage ranged from 12 to 45g (mean: 21.6g).<BR>The clinical efficacy was evaluated as "good" in 17 cases, "poor" in 6 cases and "fair" in 2 cases. The efficacy rate was thus 68%.<BR>Causative organisms were isolated in 14 patients. These organisms were eradicated in 11 patients and replaced by other organisms in 3 patients.<BR>As with side effects, skin eruption were observed in 3 cases. The abnormal laboratory test values were recorded in anemia (2 cases) and elevation of eosinophilia (7 cases).
日本感染症学会の論文